Anti Müllerian Hormone as a Predictor of Metabolic Syndrome in Polycystic Ovary Syndrome

Abstract

Objective: To evaluate whether Anti Müllerian Hormone (AMH) can be used as a predictor of metabolic syndrome in Polycystic Ovarian Syndrome (PCOS).
Methods: This cross-sectional study was conducted in Yasmin Clinic, Dr. Cipto Mangunkusumo General Hospital Jakarta between June and December 2012. Forty-one patients diagnosed with PCOS
based on Rotterdam Criteria were enrolled. Secondary were was taken from medical record..
Results: A total of 22 subjects were involved in this study. Mean AMH level in the metabolic syndrome group is compared to the non-metabolic syndrome group (10.72 Â± 6.23 ng/ml vs 7.97 Â± 4.50
ng/ml, p=0.12). AMH was strongly associated with HDL, triglyceride and insulin resistance (r-value of -0.29, 0.23, and 0.21 respectively, p < 0.05).
Conclusion: AMH can be used as a predictor of metabolic syndrome in PCOS.
[Indones J Obstet Gynecol 2017; 5-2: 83-86]
Keywords: anti müllerian hormone, metabolic syndrome, polycystic ovarian syndrome